Effect of the Ethinylestradiol/levonorgestrel Combined Oral Contraceptive on the Activity of Cytochrome P4503A in Obese Women

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2012 Feb 4

PMID 22299599

Citations 5

Authors

Alison Edelman

Myrna Munar

Miriam R Elman

Dennis Koop

Ganesh Cherala

Affiliations

Soon will be listed here.

Abstract

Aim(s): While it is known that CYP3A4/5 activity is decreased with combined oral contraceptive (COC) use and obesity suppresses CYP expression, the combined effects of obesity and COC use on CYP3A4/5 activity are unclear. Therefore, our aim was to examine the effect of COC usage on CYP3A4/5 activity in obese women.

Methods: Thirty-four, obese (body mass index, BMI > 30 kg m(-2)) women of reproductive age (18-35 years old) were placed on a COC pill containing 20 µg ethinylestradiol/100 µg levonorgestrel for 21 days starting at the onset of menses. A midazolam pharmacokinetic study was conducted prior to initiation and after 21 days of COC treatment. Serial blood samples were collected and plasma concentrations of midazolam were measured using liquid chromatography tandem mass spectrometry. Pharmacokinetic parameters were estimated using a non-compartmental method.

Results: Midazolam clearance, a surrogate measure of CYP3A4/5 activity, was significantly decreased upon COC use (63.3 l h(-1) vs. 53.9 l h(-1), P < 0.05). A median decrease of 5.6 l h(-1) (95% CI -4.1, 13.3 l h(-1)) was observed. However, the magnitude of change was similar to that reported in women with normal BMI.

Conclusions: Although we hypothesized that obesity might amplify the impact on CYP3A4/5 activity in COC users, we found that this was not the case. This finding is reassuring regarding potential additional drug-drug interactions in obese COC users as CYP3A4/5 is a major enzyme in the metabolism of many marketed drugs.

Citing Articles

Sources of Interindividual Variability.

Lin Y, Thummel K, Thompson B, Totah R, Cho C Methods Mol Biol. 2021; 2342:481-550.

PMID: 34272705 DOI: 10.1007/978-1-0716-1554-6_17.

Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy.

DuBois B, Atrio J, Stanczyk F, Cherala G Contraception. 2014; 91(1):71-5.

PMID: 25245190 PMC: 4268426. DOI: 10.1016/j.contraception.2014.08.009.

An ethinyl estradiol-levonorgestrel containing oral contraceptive does not alter cytochrome P4502C9 in vivo activity.

Cherala G, Pearson J, Maslen C, Edelman A Drug Metab Dispos. 2013; 42(3):323-5.

PMID: 24368832 PMC: 3935138. DOI: 10.1124/dmd.113.054346.

Birthweight and cytochrome P4503A4/5 activity in obese women.

Cherala G, Thornburg K, Edelman A Br J Clin Pharmacol. 2012; 75(1):275-6.

PMID: 22534035 PMC: 3555069. DOI: 10.1111/j.1365-2125.2012.04309.x.

Impact of obesity on drug metabolism and elimination in adults and children.

Brill M, Diepstraten J, van Rongen A, van Kralingen S, van den Anker J, Knibbe C Clin Pharmacokinet. 2012; 51(5):277-304.

PMID: 22448619 DOI: 10.2165/11599410-000000000-00000.

References

Cheng P, Morgan E . Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab. 2001; 2(2):165-83. DOI: 10.2174/1389200013338676. View

Heilbronn L, Campbell L . Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des. 2008; 14(12):1225-30. DOI: 10.2174/138161208784246153. View

Balogh A, Gessinger S, Svarovsky U, Hippius M, Mellinger U, Klinger G . Can oral contraceptive steroids influence the elimination of nifedipine and its primary pryidine metabolite in humans?. Eur J Clin Pharmacol. 1999; 54(9-10):729-34. DOI: 10.1007/s002280050543. View

Abernethy D, Greenblatt D, Divoll M, Smith R, Shader R . The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet. 1984; 9(2):177-83. DOI: 10.2165/00003088-198409020-00005. View

Johnson E, Schwab G, Vickery L . Positive effectors of the binding of an active site-directed amino steroid to rabbit cytochrome P-450 3c. J Biol Chem. 1988; 263(33):17672-7. View

Seaman H, de Vries C, Farmer R . Differences in the use of combined oral contraceptives amongst women with and without acne. Hum Reprod. 2003; 18(3):515-21. DOI: 10.1093/humrep/deg090. View

Mojtabai R . Body mass index and serum folate in childbearing age women. Eur J Epidemiol. 2005; 19(11):1029-36. DOI: 10.1007/s10654-004-2253-z. View

Sims S, Rehrer N, Bell M, Cotter J . Endogenous and exogenous female sex hormones and renal electrolyte handling: effects of an acute sodium load on plasma volume at rest. J Appl Physiol (1985). 2008; 105(1):121-7. DOI: 10.1152/japplphysiol.01331.2007. View

Hebert M, Easterling T, Kirby B, Carr D, Buchanan M, Rutherford T . Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther. 2008; 84(2):248-53. DOI: 10.1038/clpt.2008.1. View

10.

Horne C, Weir R, Howie P, Goudie R . Effect of combined oestrogen-progestogen oral contraceptives on serum-levels of alpha 2-macroglobulin, transferrin, albumin, and IgG. Lancet. 1970; 1(7637):49-50. DOI: 10.1016/s0140-6736(70)91841-6. View

11.

Laine K, Yasar U, Widen J, Tybring G . A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. Pharmacol Toxicol. 2003; 93(2):77-81. View

12.

Farmer R, Lawrenson R . Utilization patterns of oral contraceptives in UK general practice. Contraception. 1996; 53(4):211-5. DOI: 10.1016/0010-7824(96)00039-x. View

13.

Dinger J, Minh T, Buttmann N, Bardenheuer K . Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol. 2011; 117(1):33-40. DOI: 10.1097/AOG.0b013e31820095a2. View

14.

Zhang H, Cui D, Wang B, Han Y, Balimane P, Yang Z . Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007; 46(2):133-57. DOI: 10.2165/00003088-200746020-00003. View

15.

Ellison J, Thomson A, Greer I, Walker I . Drug Points: Apparent interaction between warfarin and levonorgestrel used for emergency contraception. BMJ. 2000; 321(7273):1382. PMC: 27541. DOI: 10.1136/bmj.321.7273.1382. View

16.

Carlstrom K, Karlsson R, von Schoultz B . Diurnal rhythm and effects of oral contraceptives on serum dehydroepiandrosterone sulfate (DHEAS) are related to alterations in serum albumin rather than to changes in adrenocortical steroid secretion. Scand J Clin Lab Invest. 2002; 62(5):361-8. DOI: 10.1080/00365510260296519. View

17.

Vahratian A . Prevalence of overweight and obesity among women of childbearing age: results from the 2002 National Survey of Family Growth. Matern Child Health J. 2008; 13(2):268-73. PMC: 2635913. DOI: 10.1007/s10995-008-0340-6. View

18.

Obisesan K, Adenaike F, Okunlola M, Adenaike A . Effects of oral contraceptives on total serum proteins, albumin, globulins and cholesterol levels in Ibadan, Nigeria. West Afr J Med. 2003; 21(3):197-9. DOI: 10.4314/wajm.v21i3.28028. View

19.

Greenblatt D, Abernethy D, Locniskar A, Harmatz J, Limjuco R, Shader R . Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984; 61(1):27-35. View

20.

Trussell J . Understanding contraceptive failure. Best Pract Res Clin Obstet Gynaecol. 2009; 23(2):199-209. PMC: 3638203. DOI: 10.1016/j.bpobgyn.2008.11.008. View